A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) -; soft tissue tumors that are stubbornly resistant to chemotherapy and radiation -; according to a laboratory study led by researchers at the Johns Hopkins Kimmel Cancer Center.